Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications

View ORCID ProfileAditi Bhatt, Naoual Bakrin, View ORCID ProfilePraveen Kammar, View ORCID ProfileSanket Mehta, Snita Sinukumar, Loma Parikh, Sakina Shaikh, View ORCID ProfileSuniti Mishra, View ORCID ProfileMita Y Shah, View ORCID ProfileVahan Kepenkian, View ORCID ProfileNazim Benzerdjeb, View ORCID ProfileOlivier Glehen
doi: https://doi.org/10.1101/2020.04.02.20048702
Aditi Bhatt
1Dept. of Surgical Oncology, Zydus hospital, Ahmedabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aditi Bhatt
Naoual Bakrin
2Dept. of Surgical Oncology, Centre Hospitalier Lyon-sud, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Praveen Kammar
3Dept. of Surgical Oncology, Saifee hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Praveen Kammar
Sanket Mehta
3Dept. of Surgical Oncology, Saifee hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sanket Mehta
Snita Sinukumar
4Dept. of Surgical Oncology, Jehangir hospital, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loma Parikh
5Dept. of Pathology, Zydus hospital, Ahmedabad, India,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sakina Shaikh
1Dept. of Surgical Oncology, Zydus hospital, Ahmedabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suniti Mishra
6Dept. of Pathology, Fortis Hospital, Bangalore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Suniti Mishra
Mita Y Shah
7Dept. of Pathology, Saifee hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mita Y Shah
Vahan Kepenkian
2Dept. of Surgical Oncology, Centre Hospitalier Lyon-sud, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vahan Kepenkian
Nazim Benzerdjeb
8India Dept. of Pathology, Centre Hospitalier Lyon-sud, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nazim Benzerdjeb
Olivier Glehen
2Dept. of Surgical Oncology, Centre Hospitalier Lyon-sud, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Glehen
  • For correspondence: olivier.glehen@chu-lyon.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Residual disease in ‘normal appearing’ peritoneum is seen in nearly 30% following neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Our goal was to study prospectively, the sequence of response in different regions, the commonest sites of occult residual disease, its incidence in different peritoneal regions and the potential therapeutic implications of these.

Methods The patterns of response were studied based on the finding of residual disease in cytoreductive surgery specimens on pathological evaluation. A protocol for pathological evaluation was laid down and followed. Informed consent was taken from all patients. A correlation between clinical and pathological findings was made. Sugarbaker’s peritoneal cancer index was used to describe the regional distribution of peritoneal disease

Results In 85 patients treated between July 2018 to June 2019, 83 FIGO stage III-C at diagnosis and 2 stage IV-A. Microscopic disease in ‘normal appearing’ peritoneal regions was seen in 22 (25.2%) and in normal peritoneum around tumor nodules in 30 (35.2%). Regions 4 and 8 of Sugarbaker’s peritoneal cancer index had the highest incidence of residual disease in absence of visible disease and regions 9 and 10 the lowest. The response to chemotherapy occurred in a similar manner in over 95% of the patients-the least common site of residual disease was the small bowel mesentery, followed by upper regions (regions 1-3), omentum and middle regions (regions 0, 4, 8), lower regions (regions 5-7) and lastly the ovaries. Nearly 85% had 4 or more peritonectomies and 67% had 6-7 peritonecomies.

Conclusions Complete resection of involved the peritoneal region could address all the occult disease in a particular region. The role of resection of the entire region as well as ‘normal appearing’ parietal peritoneal regions (or total parietal peritonectomy) during interval cytoreduction should be prospectively evaluated to determine its impact on morbidity and survival.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no funding for the study

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available on reasonable request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 06, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications
Aditi Bhatt, Naoual Bakrin, Praveen Kammar, Sanket Mehta, Snita Sinukumar, Loma Parikh, Sakina Shaikh, Suniti Mishra, Mita Y Shah, Vahan Kepenkian, Nazim Benzerdjeb, Olivier Glehen
medRxiv 2020.04.02.20048702; doi: https://doi.org/10.1101/2020.04.02.20048702
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications
Aditi Bhatt, Naoual Bakrin, Praveen Kammar, Sanket Mehta, Snita Sinukumar, Loma Parikh, Sakina Shaikh, Suniti Mishra, Mita Y Shah, Vahan Kepenkian, Nazim Benzerdjeb, Olivier Glehen
medRxiv 2020.04.02.20048702; doi: https://doi.org/10.1101/2020.04.02.20048702

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5206)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (747)
  • Geriatric Medicine (76)
  • Health Economics (212)
  • Health Informatics (691)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5798)
  • Intensive Care and Critical Care Medicine (355)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1987)
  • Radiology and Imaging (342)
  • Rehabilitation Medicine and Physical Therapy (155)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)